AZ PRMT5i 1
Alternative Names: AZ-PRMT5i-1; MTAP-selective-PRMT5-inhibitorLatest Information Update: 01 Feb 2024
At a glance
- Originator AstraZeneca
- Class Antineoplastics; Spiro compounds
- Mechanism of Action PRMT5 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Cancer
Most Recent Events
- 09 Dec 2023 Pharmacodynamics data from a preclinical trial in Hodgkin’s Lymphoma presented at the 65th American Society of Hematology Annual Meeting and Exposition (ASH-Hem-2023)
- 14 Apr 2023 AstraZeneca plans a phase I trial for Cancer
- 14 Apr 2023 Preclinical trials in Cancer in United Kingdom (unspecified route)